PMID- 37006081
OWN - NLM
STAT- MEDLINE
DCOM- 20230404
LR  - 20230404
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 19
IP  - 2
DP  - 2023 Jan-Mar
TI  - Co-administration of pazopanib and enteral nutrition with omega-3 fatty acids as 
      a safety issue in a patient treated for metastatic clear cell renal cancer: A 
      case report.
PG  - 474-476
LID - 10.4103/jcrt.jcrt_533_22 [doi]
AB  - Pazopanib is an oral multitargeting tyrosine kinase inhibitor (TKI) of vascular 
      endothelial growth factor receptors (VEGFRs), approved as the first-line 
      treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma (STS) 
      at a fixed dose of 800 mg daily taken fasted. Potential drug-meal interactions 
      and adverse events (AEs) may lack recognition and the related data in literature. 
      We report one case of stomatitis/oral mucositis associated with pazopanib 
      administrated with an oral nutritional supplement enriched with omega-3 fatty 
      acids. The 50-year-old patient with mRCC started pazopanib treatment at standard 
      doses of 800 mg daily as first-line therapy for mRCC, and after a few days, he 
      developed stomatitis. Co-administration of pazopanib with high-fat meals could 
      increase the solubility of highly lipophilic pazopanib, increasing its plasma 
      pazopanib area under the curve (AUC), and maximum concentration (Cmax) above 
      optimal therapeutic level can consequently lead to increased frequency/grade of 
      AEs.
FAU - Zlatovic, Josipa Jovic
AU  - Zlatovic JJ
AD  - Department of Internal Medicine, General Hospital of Sibenik-Knin County, 
      Sibenik, Croatia.
FAU - Omrcen, Tomislav
AU  - Omrcen T
AD  - Department of Oncology and Radiotherapy, University Hospital Split, Split, 
      Croatia.
FAU - Marijanovic, Inga
AU  - Marijanovic I
AD  - Department of Oncology, University Clinical Hospital Mostar, Mostar, Bosnia and 
      Herzegovina, Balkans, Bosnia and Herzegovina.
FAU - Kraljevic, Marija
AU  - Kraljevic M
AD  - Department of Oncology, University Clinical Hospital Mostar, Mostar, Bosnia and 
      Herzegovina, Balkans, Bosnia and Herzegovina.
LA  - eng
PT  - Case Reports
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 7RN5DR86CK (pazopanib)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Fatty Acids, Omega-3)
SB  - IM
MH  - Male
MH  - Humans
MH  - Middle Aged
MH  - *Carcinoma, Renal Cell/pathology
MH  - *Kidney Neoplasms/drug therapy/pathology
MH  - Vascular Endothelial Growth Factor A
MH  - Enteral Nutrition
MH  - *Fatty Acids, Omega-3/therapeutic use
OTO - NOTNLM
OT  - Food-drug interaction
OT  - pazopanib
OT  - renal cell carcinoma
OT  - stomatitis
OT  - toxicity
EDAT- 2023/04/04 06:00
MHDA- 2023/04/04 06:42
CRDT- 2023/04/03 02:49
PHST- 2023/04/04 06:42 [medline]
PHST- 2023/04/03 02:49 [entrez]
PHST- 2023/04/04 06:00 [pubmed]
AID - JCanResTher_2023_19_2_474_371871 [pii]
AID - 10.4103/jcrt.jcrt_533_22 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2023 Jan-Mar;19(2):474-476. doi: 10.4103/jcrt.jcrt_533_22.